35 results about "Collagen-induced arthritis" patented technology

An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for induction of oral tolerance and that K1 is involved in mediating this function.

The invention discloses a polypeptide for inhibiting joint inflammations in mice and application thereof. The micro-molecule polypeptide SJMHE1 originated from the egg and imago antigens of Schistosoma japonicum consists of 24 amino acids, is a T cell epitope shared by human and mouse HSP60 molecules, and can prevent and treat collagen-induced arthritis in mice. The polypeptide of the invention has the beneficial benefits that the polypeptide can be used for treating rheumatoid arthritis and has potential new drug development value.

The present invention provides a model animal with favorite onset of rheumatoid arthritis wherein the severity of arthritis reaches the maximum level and its onset ratio is a hundred percent, and a screening method of a remedy for rheumatoid arthritis by using the model animal. A mouse whose function of immunoglobulin Fcγ receptor IIB gene is deficient on its chromosome and a wild-type collagen-induced arthritis-susceptible DBA / 1J mouse are backcrossed six times or more, and a model mouse with favorite onset of rheumatoid arthritis is constructed. This model mouse with favorite onset of rheumatoid arthritis is immunized with bovine joint-origin type II collagen to develop collagen-induced arthritis.

The invention relates to a Myricaria germanica effective part, a preparation method and use thereof in treatment of rheumatism and rheumatoid arthritis. Animal experiments prove that the effective part can inhibit croton oil induced mouse ear swelling and rat adjuvant or collagen induced arthritis, and can be used for prevention and / or treatment of rheumatism and rheumatoid arthritis.

The liposome dimethylcurcumin is a liposome-encapsulated dimethylcurcumin (Lipo-DiMC). Dimethyl curcumin is a synthetic curcumin analog with the chemical formula C23H24O6. Compared with curcumin and dimethyl curcumin, Lipo- DiMC has better metabolic stability and is highly water soluble and has a sustained release effect in vivo. In some inflammatory, autoimmune and cancer diseases, Dipeptidyl peptidase (DPPI) and Matrix metalloproteinase (9, MMP-9) are overexpressed, leading to changes in tissue microenvironment and in vivo. Balance disorders and cause cell reproductive disorders. In the ratmodel of collagen induced arthritis (CIA) treated with Lipo-DiMC, Lipo-DiMC alleviated the swelling of the toes of CIA rats and inhibited DPPI and MMP in body fluids, blood and spleen lymphocytes of CIA rats-9 Overexpression of activity. The in vitro rat spleen lymphocyte model further confirmed that Lipo-DiMC inhibited and regulated the DPPI activity and MMP 9 expression and secretion in rat spleen lymphocytes.

The invention provides application of general inula helenium sesquiterpene lactone in preparation of a medicine for treating rheumatoid arthritis. The general inula helenium sesquiterpene lactone contains alantolactone and isoalantolactone; and the sum of the contents of the alantolactone and the isoalantolactone accounts for 60 to 90%. The results of animal pharmacodynamic tests show that the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can inhibit the clinical onset of CIA (Collagen-induced Arthritis), obviously inhibit the morbidity of CIA, obviously reduce the level of IFN(Interferon)-gamma, and remarkably inhibit the generation of IL(Interleukin)-17. Therefore, the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can be used for preparing the medicine for treating rheumatoid arthritis. The medicine is composed of the general inula helenium sesquiterpene lactone serving as an active ingredient and a pharmaceutic adjuvant and can be in form of a troche, a capsule, a soft capsule, a dropping pill, granules, an injection, a powder-injection or an aerosol and the like. The medicine provided by the invention is a new medicine for treating rheumatoid arthritis, which has remarkable curative effect and little side reaction; the raw materials are conveniently obtained, the preparation method is simple, and the medicine has relatively high clinical application value.

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p161nk4a and p21Cip1 in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Clip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.

The present invention discloses a novel carbazole amide derivative or its salt represented by the general formula I with RORγt activity regulating effect and a preparation method thereof, and also discloses the use of the carbazole amide derivative or its salt in preparing therapeutic Use in medicine for diseases associated with RORγt. Experimental results show that the carbazole amide derivatives of the present invention or their salts can effectively regulate the activity of RORγt protein receptors, thereby regulating the differentiation of Th17 cells and the production of IL-17, and further serve as therapeutic drugs for the treatment of related diseases mediated by RORγt , especially for the treatment of multiple sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel disease, encephalomyelitis, clonal disease, asthma and various cancers and other related diseases.

The invention discloses Artemisia japonica homogeneous polysaccharides as well as a preparation method and an application thereof. The Artemisia japonica homogeneous polysaccharides are obtained through column chromatographic separation and purification after water extraction and alcohol precipitation of all grass of Artemisia japonica, are inulin type fructan which is connected by fructose through 1,2 and contains a glucosyl group at the terminal, contain no uronic acid and have the weight-average molecular weight ranging from 1 kDa to 20 kDa. Experiment results indicate that the Artemisia japonica homogeneous polysaccharides can obviously reduce the foot swelling degree of mice suffering from collagen-induced arthritis and levels of inflammatory factors IL-6 and IL-17A in serum of the mice, are expected to be used as a major or unique active ingredient for preparation of health-care food or pharmaceutic preparations for preventing or / and treating rheumatoid arthritis, and have the important significance in research and development of Artemisia japonica pharmaceutic preparations having the clinical application value; besides, the preparation method is simple, high-purity Artemisia japonica homogeneous polysaccharides can be obtained, and the method is suitable for large-scale production and good in practicability.

The invention belongs to the technical field of chemical medicines, and relates to a bridge ring piperazine derivative or salt thereof, a preparing method of the derivative and application of the bridge ring piperazine derivative or salt thereof in preparing medicines for treating ROR gamma t related diseases. Through experiments, the result shows that the bridge ring piperazine derivative can effectively restrain ROR gamma t protein receptors, adjust the differentiation of Th17 cells and restrain the generation of IL-17, can further be used as the treatment medicines for treating the ROR gamma t mediated inflammation related diseases and is particularly suitable for treating the inflammation related diseases such as disseminated sclerosis, rheumatoid arthritis, collagen induced arthritis,psoriasis, inflammatory bowel disease, encephalomyelitis, cloning diseases, asthma and cancers. The chemical formula can be seen in the description.

The invention discloses the application of low-molecule heparin in preparing medicaments for treating collagen-induced arthritis. The invention provides the application of the low-molecule heparin in preparing the medicaments for treating rheumatic diseases, wherein the rheumatic disease are chronic infectious arthritis. The invention has the advantages of exploring the purpose medical treatment of the low-molecule heparin and developing a new application field. The result indicates that the low-molecule heparin has the function of restraining the synovium inflammation of the chronic infectious arthritis and has one of purposes of restraining the adhesion of synovial fibroblast cells and inflammatory cells. The result provides the experimental basis for seeking biological treating target spots and other small-molecule treating target sports, and the low-molecule heparin has clinical application values.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

The invention discloses a total lignan extract of stalkedfruit pricklyash bark, which is characterized in that the content of total lignan is above 30%. The total lignan extract of stalkedfruit pricklyash bark is extracted and refined from the traditional Chinese medicine stalkedfruit pricklyash bark. Proven by pharmacodynamical and toxicological tests, the total lignan extract of stalkedfruit pricklyash bark can obviously improve the collagen induced arthritis of rats, and simultaneously has better analgesis and anti-inflammation effects with small toxic side effects. The invention also discloses a medical application of the total lignan extract of stalkedfruit pricklyash bark.

The invention provides an application of a traditional Chinese medicine huanglian jiedu decoction (comprising the Chinese medicine components of 9g of coptis chinensis, 6g of scutellaria baicalensis, 6g of golden cypress and 9g of gardenia) in preparing a medicament for preventing and treating rheumatoid arthritis. When being used for animal pharmacodynamic test, the huanglian jiedu decoction is proved to have the functions of restraining the clinical pothogenesy of CIA (Collagen-Induced Arthritis), obviously restraining the severity and the morbidity of the CIA and having obvious protection function to the CIA. The huanglian jiedu decoction can reduce the contents of TNF-alpha, IL-17 and IFN-gamma in splenocyte supernatant and restrain the secretion of proinflammatory cytokine, i.e. TNF-alpha, IFN-gamma and IL-17, thereby playing a protecting role for the CIA disease. The invention provides a new traditional Chinese medicine for clinically treating rheumatoid arthritis, which can overcome the toxic and side effects of pharmaceutical chemicals, thereby bringing confidence for treating and achieving higher clinical application value.

The invention discloses Artemisia japonica homogeneous polysaccharides as well as a preparation method and an application thereof. The Artemisia japonica homogeneous polysaccharides are obtained through column chromatographic separation and purification after water extraction and alcohol precipitation of all grass of Artemisia japonica, are inulin type fructan which is connected by fructose through 1,2 and contains a glucosyl group at the terminal, contain no uronic acid and have the weight-average molecular weight ranging from 1 kDa to 20 kDa. Experiment results indicate that the Artemisia japonica homogeneous polysaccharides can obviously reduce the foot swelling degree of mice suffering from collagen-induced arthritis and levels of inflammatory factors IL-6 and IL-17A in serum of the mice, are expected to be used as a major or unique active ingredient for preparation of health-care food or pharmaceutic preparations for preventing or / and treating rheumatoid arthritis, and have the important significance in research and development of Artemisia japonica pharmaceutic preparations having the clinical application value; besides, the preparation method is simple, high-purity Artemisia japonica homogeneous polysaccharides can be obtained, and the method is suitable for large-scale production and good in practicability.